1. “FDA approves Zydelig for three types of blood cancers”. US Food and Drug Administration. July 23, 2014.
2. “FDA approves new treatment for adults with relapsed follicular lymphoma”. US Food and Drug Administration. September 14, 2017.
3. “FDA Approval for duvelisib (COPIKTRA, Verastem, Inc.) for adult patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL)”. US Food and Drug Administration September 24, 2018. September 24, 2018.
4. “FDA approves first PI3K inhibitor for breast cancer”. US Food and Drug Administration 2019-05-22019-05-24.
5. Raedler LA. Zydelig (Idelalisib): First-in-Class PI3 Kinase Inhibitor Approved for the Treatment of 3 Hematologic Malignancies. American health & drug benefits. 2015;8(Spec Feature): 157-162.